These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 31102154)

  • 1. Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.
    Le QV; Suh J; Oh YK
    AAPS J; 2019 May; 21(4):64. PubMed ID: 31102154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.
    Liu Y; Guo J; Huang L
    Theranostics; 2020; 10(7):3099-3117. PubMed ID: 32194857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
    Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
    Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy.
    Mei Y; Wang R; Jiang W; Bo Y; Zhang T; Yu J; Cheng M; Wu Y; Cheng J; Ma W
    Biomater Sci; 2019 Jun; 7(7):2640-2651. PubMed ID: 31090764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
    Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
    J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy.
    Xing H; Li X
    Chemistry; 2024 Jun; 30(32):e202400425. PubMed ID: 38576219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon-Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment.
    Saleem J; Wang L; Chen C
    Adv Healthc Mater; 2018 Oct; 7(20):e1800525. PubMed ID: 30073803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment.
    Jin Y; Huang Y; Ren H; Huang H; Lai C; Wang W; Tong Z; Zhang H; Wu W; Liu C; Bao X; Fang W; Li H; Zhao P; Dai X
    Biomaterials; 2024 Mar; 305():122463. PubMed ID: 38232643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy.
    Chen Z; Yue Z; Yang K; Shen C; Cheng Z; Zhou X; Li S
    Adv Healthc Mater; 2023 Oct; 12(26):e2300882. PubMed ID: 37539730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.
    Jiang Z; Zhang W; Zhang J; Liu T; Xing J; Zhang H; Tang D
    Int J Nanomedicine; 2022; 17():4677-4696. PubMed ID: 36211025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomaterials for cancer immunotherapy.
    Song W; Musetti SN; Huang L
    Biomaterials; 2017 Dec; 148():16-30. PubMed ID: 28961532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomaterial-Based Tumor Photothermal Immunotherapy.
    Xu P; Liang F
    Int J Nanomedicine; 2020; 15():9159-9180. PubMed ID: 33244232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression.
    Zhang C; Yan Q; Li J; Zhu Y; Zhang Y
    ACS Appl Bio Mater; 2021 Jan; 4(1):277-294. PubMed ID: 35014284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
    Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
    Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomaterials for T-cell cancer immunotherapy.
    Gong N; Sheppard NC; Billingsley MM; June CH; Mitchell MJ
    Nat Nanotechnol; 2021 Jan; 16(1):25-36. PubMed ID: 33437036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
    Lan H; Zhang W; Jin K; Liu Y; Wang Z
    Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.